Healthcare News 13

• "Fatty liver", "deadly quarter" etc.: update on German research.
• "Health-care costs are expected to rise more than 10% ".... and we can continue this for how long??
• "Star Wars" technology interfaces with radiation oncology
• “Amgen told to reword drug label” – this title can be evaluated from different points of view: 1. Amgen loss of profits; 2. FDA’s authority; 3. Real benefits for cancer patients.
• 1st Chartless office in Tenn.
• 3 week radiation for breast cancer: What is the cosmetic end result?
• 3 weeks IS as good!
• 30:70 chance of approval
• A bit misdirected?
• A Complex Personal and Societal Issue
• A Faulty Track-and-Trace Cost Model for Pharmacies
• A Foot in the Pediatric Door?
• A Good Intermittent and Intermediate Treatment
• A Growing Problem
• A need for cost effective ASP model EHR solution
• A new Contact Lens material by 2009?
• A new gliptin - what is the difference to sita- and vildagliptin?
• A new lens for computer users?
• A Pill For Every Mouth
• A Real Answer to a Real, if Low-incidence Problem
• A rough in the diamond
• A Small Company, A Big Idea
• A Tenuous Connection at Best
• A Transparent Health System - a Platform for Health Reform
• A Word to the Wise...
• Abbott Wants Seat At The Adults Table At Last!
• About time !
• Absolutely NOT!
• Access to physicians saved...for now!
• ACE Inhibitors Decrease Cardiovascular Events in Marfan's Syndrome.
• ADHD parent training programs will not likely be effective in the US
• ADHD Strategies: Parental Focus
• Adolescent Acne - Many Treatments, Few Cures
• Adolesecnt acne treatable
• Agreement with Abbott will help Crestor sales
• All brawn and not enough brains
• All In One Glucose System Not For All
• Allergan and Aczone: Likely a Winning Combination
• Allergan's acquisition of Aczone- is this significant?
• Amgen and J & J: Not hurt as much as we had predicted.
• Amgen as well as J & J: Adding insult to injury......
• Amgen Rewords Label: Less Use of Procrit
• Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
• Amgen's long awaited product to treat chronic ITP will be well receive.
• An illegal use of Lumigan, now legal?
• An under-rated area of investigation, with real potential for clinical application
• And yet, another filler? Is this the Holy Grail?
• Anesthetic factors that modulate postoperative pain
• Another Item Which Patients "Want", and Cost be Damned
• Another reason why government intervention doesn't work
• Antimicrobial resistant bacteria not "superbugs"
• Antipsychotics are not just "overused" - they increase mortality and morbidity.
• Anything new for Alzheimer's patients - a development or a dilemma ?
• APOSENSE® [18F]-ML-10- A novel Apoptosis Imaging Agent
• Arm Chair Analysis from Monday Morning Quarterbacks provides unrealistic expectations and inappropriate rules
• Artificial red blood cells (RBC'S): preliminary but very promising.
• As if Rituxan (Genentech/Biogen) needed another market?
• as medicine becomes an expected no cost right it looses value & reimbursement
• Astra-Zeneca and Abbott partner on promoting Crestor..should Pfizer beware?
• At What Cost Prevention?
• Avastin Effecitve in Lung and Breast Cancer But is it Cost Effective?
• Avastin for front-line treatment of metastatic breast cancer: Not a big market
• Avastin is inexpensive for Macular Degeneration therapy
• Avastin may not get approval of "cost-conscious" EMEA
• Avastin use in breast ca in the EU? No surprise but does it prolong survival?? Who is the winner??
• Avastin/Tarceva/Roche/OSI/Genentech: So much for "synergy" in lung cancer
• Avastin: Worth the Cost?
• Avoiding the Appearance of Improper Conduct in Research
• Azilect
• BAD news
• Bad News (but not new news) for stents.
• Bayer AG Buyout to Jump Start its Ongoing Biotech Program
• Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
• Bcl-2 apoptosis inhibition: The next "best" thing?
• Be very careful
• beauty salon or clinic?
• Behavioral change aint easy for physicians regardless of data
• Being rich and lean is better than being poor and obese.
• Best acne care product I've seen.
• Beta trial negative, but is it truely blinded
• Bigger concerns about Abacavir than HLA testing
• Bill seeks to force doctor's hand with Electronic Reords.
• Biomarker for sepsis.
• Biostatistical and Experimental Design Assessment of Research on Tau Tangle Targeting for Alzheimer’s Disease
• BiovaxID: Does It Work?
• Boomers numbers and demands point to increased demand for medical real estate
• Bottle Feeding, Teething & Seething Toxins
• Bottle Feeding, Teething & Seething Toxins
• Boy will this p.... off Urologists as well as AARP!
• BPA uncertainty will cause short-term opportunity regardless of ultimate conclusions
• Byetta - what needs to be done
• byetta / LAR will be multi-billion dollar drug
• Byetta Preventing Mortality? Even IF True, Wrong Formulation?
• Byetta sale will reduce after FAD alert
• Byetta sale will remain assuch or decrease
• Byetta saves lives
• Byetta Saves Lives
• CA E-Pedigree Delayed to 2015
• California Debates a Tougher Drug Supply Chain Law
• Can China Make Generics Better than They Make Toys
• Can E-Prescribing Pay for Itself?
• Can physicians adapt to proposed IT requirements?
• Canadian Experience with Evolence
• Cancer Care Is getting out of reach
• Cancer Diagnosis and Treatment Among High Profile Celebrities and Public Figures
• cancer incidence falls drammatically after age 85
• Cardinal Health Finally Resolves DEA Issue
• Cardinal Health Invests in China
• Cardiology:Do Beta Blockers Truly Harm Non-Cardiac Surgical Patients?
• CBT and neuromodulation are underutilized.
• Cerberus Reportedly Shopping Talecris Biotherapeutics to Competitors
• Cervical Cancer Vaccines: Hope or Hype?
• Chinese Food For Prevention?
• Choose your patient wisely.
• Clinical Trials Go Unpublished
• CMS Core Measures success is about documentation
• cold medications overdose- med fault or Dr. fault?
• Cole & Pfizer: Happy together in NSCLCA (non small cell lung cancer)
• Combination of unknown and known components is advertised to cure any cancer and coronary artery disease!
• Competitive Bidding Demo Repealed by House of Representatives
• Complicated issue
• Concerns about Evolence being successful.
• Concerns about the Rember Phase 2 data
• Controlled Substances: Can be a Hot Commodity in the Wrong Hands
• COPD Drugs - Some safer than others
• Cost implications of July 1-2 FDA panel
• Cost vs Efficacy: A conundrum for insurers, physicians and patients.
• Costly cancer drugs have to be cost-effective
• Could be a smart move or could backfire
• Could the Congress Have an Election Year Surprise for the Health IT Industry?
• COURAGE - flawed trial as it compares optimum medical therapy with sub-optimum PCI
• Courage trial should redefine care in America
• Cure is a strong word
• Current use of Abacavir
• daily care for cane for adolescents and young
• Dangers of Methadone Usage
• Delay in price tagging - who to blame?
• Dermatologists? I worry more about the Family practitioners, Ob-Gyns, and Internists...
• Desperate times- desperate measures
• Diabetes: Let's avoid pseudoscience and start over.....
• Different reimbursement systems for oral and infusion drugs corrupts the drug use process
• Different Strategy Rather Than A Difference By Agent Used
• DIfficult market to jump into.
• Dinosaurian problem - no easy solution for Glaxo but an interesting approach
• Disclosure of Payments to Doctors will be the Norm
• Disturbing but not so surpiring
• Doctor payments- the underlying industry
• Doctors and cancer medications: the pressure should be shifted to health plans
• Doctors are in the middle of a large financial battle.
• Doctors don't profit from EHRs
• Doctors need financial assistance to pay for Electronic Medical Records (EMR) systems
• Does Staar have an alternative to Lasik?
• Don't expect vested interests in intensive glucose lowering in type 2 diabetes to give up that easily
• Don't use a dangerous fix for for a probem that may not exist!
• drug discovery driven by patient population
• Drug Importation and Global Wholesalers
• Drug maker plans to disclose payments to doctors
• DRUG VERSES FOOD-IMPORTANCE HOW MD CAN HELP THEIR PATIENT
• Durable efficacy of exenatide for the treatment of type 2 Diabetes
• Economic Forces Leading to Use of More Generic Medications
• Economics 101 - EHR adoption will increase when it makes economic sense
• Economics of reduced prescription use causes a rise in medical costs to hospitals and the Nation
• EGFR and Non Small Cell Lung Cancer ( NSCLCa)
• Electronic Health Records - implementation hurdles
• Electronic health records: need to improve either quality or quantity of medical care delivered.
• Electronic Medical Records-EMR
• Electronic Prescribing Bonus Surprise in the Legislation to Halt Medicare Pay Cuts
• Electronic Records?? Great but.......
• EMRS
• Epo & Stroke: The chickens coming home to roost.
• Erbitux (BMS/ImClone) in Lung Ca: Finally some meat??
• Erbitux may add to chemotherapy in a subset of NSCLC patients
• Evidence shaky to begin with.....
• Evolence Approval- what effect will it have on the filler market
• Evolence: Will this New "Advanced" Collagen Filler Take Hold?
• exenatide
• Exenatide may provide practical and cost convenient efficacy in tratment of Metabolic Syndrome patients
• Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
• False economy by companies
• Faster radiation delivery is as good as conventional radiation treatment.
• FDA Restrictions on ESA's Will Have Minimal Effect of EPO Usage.
• FDA warnings on safety of Byetta and clinical impact
• FDA will ask for more data
• Federal Government Value Based Purchasing of Healthcare Set to Grow
• Federal Govt. Should be the cost
• Feds Finally Publish a Strategic Plan for Widespread Health IT Adoption
• First serum ELISA for hepcidin
• Flexibility of company shows at outset
• Focus on hypertension and cholesterol to reduce heart disease in type 2 diabetes
• Fractures from Fosamax???
• Full Disclosure of Pharmaceutical Companies Payments to Physicians to Become the Norm
• Further evidence that government intervention is around the corner
• Gene Targeted Drug Therapy for Heart Failure
• Generic Drug Profits: Too High or Appropriate Incentive?
• Genetic testing initially will promote Chaos and misinformation
• Get rid of fast food.
• Getting Even Less than What We're Paying for in Healthcare
• GIST: So what else is new.....
• GlaxoSmithKline (GSK): treatment of obesity
• Good and no good
• Good Documentation of Common Knowledge
• Good move but at what expense?
• Good news
• Government Driven Electronic Health Records
• Government Health Service - A Disgrace
• Government Intervention is Here: Pharma had better get use to it....
• Government is hindering good surgical care
• Great Concept, Unfortunately, No Reliable Marker
• Greed wins again!
• Growing market for nutraceuticals.
• GSK completes pediatric DTP+ line with (awfully named) Kinrix
• GSK is going after Genentech's (Herceptin) Cookies....
• GSK's Lapatanib: ways from competing with Herceptin
• Hair Removal: An Expanding Market
• hair systems in the marketplace
• Healtcare IT Now pushes for IT funding
• Health IT Legislation in Congress--Now or Later?
• Health supplements todays need for India
• Healthcare business economics
• Healthcare Consumers Are More Savvy
• Healthcare industry NOT immune to economic illness
• Healthcare IT Standards Remember May Day on Wall Street? Jeff Leston Catlestone Advisors
• Healthcare Reform Beckons Again: This Time the Stars may be in Even Better Alignment
• Healthways A Market Downturn and Results
• Heart attack and Cardiovascular disease increased with anticholinergics
• Hepcidine quantification is a valuable tool for iron balance analysis
• Heroic attempt of Medtronic to safe stenting market.
• Highly Promising Phase III Trial of Baxter's IVIg for Alzheimer's Disease Begins
• HIV drugs can not be used as prevention
• HLA screening for ABV hypersensitivity reaction
• home acne devices
• Hospital Death Rates No Longer a Secret
• Hospital transparency an illusive ideal
• How are we to pay for computers with a 10% drop in Medicare fees?
• How to identify individuals likely to benefit from the use of Statins.
• How true!
• Huge Market for Cetuximab
• Hypoglycemia might be as bad as hyperglycemia.
• Hypoglycemics will now be hyperscrutinized as monotherapies and maybe even adjuncts.
• I agree that EMRs are not ready for most of us primary care doctors...
• I know, I know there is no money in diagnostics but....
• I know, there is no money in diagnostics, BUT.......
• I totally agree with the fact that currently the dermataologists are avoiding the skin cancer patients in favor of the filler and Botox cleients. If howver the third party insurers would compensate the physicians for their skin lesion removals properly this might not be occuring a sit is.
• Idera Pharma: is there room for another agent in recurrent renal cell ca??
• If it bleeds, it leads: "anaesthetics can make the pain worse".
• If you've done everything else, there is nothing else
• Imaging and therapeutic agents for Brain tumor ( glioblastoma multiforme)
• Implications of Psychiatrists Doing Relatively Less Psychotherapy and More Psychopharmacology
• Important Public Health Study
• Improving the "Tired Look" - How to Treat Dark Circles Under Eyes
• Improving the Quality of Life while living in our means
• Improving the quality of work with electronical advancement at US Hair Restoration
• In Maps of Cancer, the Analysis is the Problem
• Industry Funded Research- Sometimes Tainted But Necessary For Medical Progress
• Infectious Diseases
• Interesting, but be cautious
• Intermittent Use of Topical Tacrolimus in Stable Atopic Dermatitis
• Is Alimta (Lilly) the answer? (What is the question?)
• Is Biodel's argument to drop the India data from analysis valid?
• Is this a precautionery measure or a step to safeguard patient's health?
• Issues with Ustekinumab
• It is ALL about the size of the scar.
• It will cost moe tim and Money Dealing with China
• IT'S A SHAME!
• IT'S ALIVE!!?? Astra Zeneca's (AZ) Iressa (At least in Japan)
• Its all about the spin
• It's All in the Eyes
• It's not the sugar "stupid," since type 1 diabetics are not prone to macrovascular problems. This study is inherently flawed. Insulin levels were not checked.
• Jeff is in accounting not a healthcare provider.
• Joint replacement surgery is a trade not a visit to the fountain of youth
• Killer gas from basement is a cause of lung cancer.
• Lack of price transparancy is the main hurdle towards moving to a free market medical system
• Laser is better than Steroids in the Management of Diabetic Macular Edema.
• Less and less evidence to favor coronary stenting
• Less Prescription Use May Lead to More Health-Care Expenses
• Let's Try to be Selective in What we Test for and Treat
• Life-extending effect of Byetta ?
• Lilly is replacing oine of its compounds with another in a subset of NSCLC
• Lilly to Disclose Payments to Doctors: What a revolting development this is!
• Link to Pancreatitis is Bound to Negatively Impact Byetta Sales
• Liraglutide provides better blood glucose control than exenatide
• Looks like the Britons don't care anyway...
• Lundbeck Reveals Mechanism of Action of its “Mixed Serotonin Modulator and Stimulator” Antidepressant LuAA21004
• Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
• Lung Cancer Screening: Here we go again.
• mab12
• mAbs and new Ab-like platforms offer greater specificity and fewer off-target effects
• Madu strip and magnetic trap, promising devices in medicine
• Major Potential Benefit for Small Numbers of Patients
• Massachusetts Follows Up its Universal Coverage Law with Health IT Mandates
• Medical treatment -- the unacknowledged Tragedy of the Commons
• Medicare - Carrot and the Stick!
• Medicare fee cuts: Saved by someone who may appreciate the significance........
• Medicare's Perfect Storm: Losing Primary Care
• Medication is the Mainstay of ADHD Treatment
• Melanoma: The Holy Grail at Last??
• Microsoft and Google Join with Consumer Groups to Address Health Privacy Concerns
• Mild PAH improved by early treatment with bosentan
• Minimal Impact on Stent Market
• Mixed Blessings for Medtronic in Professional Spinal Surgery Organizations
• Molecular profiles in lung cancer: THE FUTURE IS HERE....
• Molecular Profiling for Epo Stimulating Agents: Trying to 'Stop the Bleeding'
• Monoclonal Antibodies are the drugs of the future
• More of the Same Crackdown on Amgen's Epo Agents
• More questions than answers:
• More Study is Certainly a Good Thing
• MULTI EFFECT ON SINGLE DRUG DELIVERY-SRIMEERA ASSOCIATES, CHIEF MENTOR
• multi target design ligands
• Mutiple causes for no publications of many reports on FDA approved drugs.Some problems and solutions.
• Narrowing the Category of "Carcinoma of Unknown Primary" Site-- still a ways to go
• National Quality Forum Sets Health IT Standards
• Nationwide Electronic Health Record Network Pegged at $150 Billion
• Need to use these meds correctly
• new hope to improve diabetes control
• New blood-based test for colorectal cancer
• New Developments in Sepsis Diagnostics
• New electrode may expand the capabilities of the Advance System from Neurometrix
• New Health IT Bill Promises Big Bucks to Hospitals and Physicians for Electronic Records
• New Mass Spectrometers Introduced and Current Use of "UPLC" from Recent American Society on Mass Spectrometry Conference
• New non steroidal anti-inflamatory for diabetic retinopathy?
• New Therapeutic Avenue for PDE5 inhibitors: Relief of Lower Urinary Tract Symptoms in BPH
• New Twists for the AWP/First Databank Settlement
• New Use for old drugs is something good-and called clinical research.
• New uses for old meds- benefit or drawback?
• Next-Generation Xolair (omalizumab) sounds pretty good
• NICE States Novel Therapies for Renal Cell Cancer Too Costly
• No advancement in treatment
• NO ECONOMIC SHOCK TO HEALTHCARE
• No Point to This at All
• NONE
• Not All That Shines is Gold
• Not Enough Incentive
• Not too surprising a result
• Notice the last vote on medicare HR6331
• Notice the US is not part of the discussion?
• Novel Test for Appendicitis
• Novo Nordisk's Diabetes drug liraglutide is promising
• Obesity: Higher Healthcare Costs, Lower Productivity
• Oh, Good, Not only won't seniors be able to understand it; they won't be able to afford it?
• OLD news, but positive results and higher visibility will definitely benefit Bayer
• One Drug Many Uses: Prove It
• One Drug, Many Uses -- Mostly a Very Good Idea
• Onglyza - ? engagement ring for Astra Zeneca and Bristol-Myers Squibb
• Onglyza (saxagliptin) has a great scope for Diabetes-II
• ON-Q All-in-one Blood Glucose Monitoring System
• Our Kids on Statins...........Not!
• Over Suppression of Bone Turnover May Be Harmful
• Overdramatization
• Overmedication, and underdiagnosis, are commonplace in the dementia patient
• Pain may be caused by anesthesia
• Pancreatitis has the Potential to Kill (Byetta Sales)
• Patients Overwhelmingly want their Physicians to Use Electronic Medical Records
• Patients Should Only Seek Care from Licensed Healthcare Professionals
• Patients will continue to decrease the use of these agents for reasons that I can speculate are largely related to lack of perceived efficacy the fear of the unknown
• PBMs and Big PhRMA fiddle while the health care system burns
• PCI numbers will not drop after Courage
• Peer reviewed literature on Ambrisentan, a selective ETRA for PAH
• Perspectives for utilization of a new magnetic device
• PET with semiconductor shows promising result to diagnose diseases at an early stage
• Pfizer focuses down - but at the same time takes on more risk
• Pharma may benefit from both new drugs and new uses for old drugs
• Pharmaceutical Cost Transperancy
• Pharmacogenetic Tests for Antidepressants Disappointing So Far
• PhRMA Fairy Tale is Over
• PhRMA wants to have their cake...then eat it too!
• Physician Congratulates Eli Lily and Co. for Disclosing Gifts to Doctors
• Pipeline or Preening for an Aquirer?
• Pitfalls of prophylactic HIV drug usage.
• Poise Trial: more challenging questions than answers
• POISE: don't let it change your practice
• Political action statements
• Poor Economic Conditions Affect All Sectors
• Positive Clinical Results of Amylin's Exenatide LAR But Quality Issues May Determine Its Approval
• Possible Impact Of Recently Reported Fractures On The Use Of Alendronate
• possible use of chinese rice extract after cardiac bypass surgery
• Post-industrial pharma: delivering innovation
• Potential Side Effects May Take Years to Become Visible
• Progress on Federal Pedigree Will be Slow
• Promising start but more data needed
• Prospering under Pay for Performance will Require Clearing an Ever Higher Quality Bar
• Proton beam therapy has no proven advantage
• Proton Centers not yet ready for everyone.
• Proton Radiotherapy: A Review
• Protopic use can prevent relapse
• Psychiatrists have abandoned therapy
• Psychotherapy may save money
• Psychotherapy Saves Money
• Published Evidence Bias: Approved Drugs Are Just the Tip of the Iceberg
• pump review
• Race to Market, with Competition Hot on Heels
• Radon & Lung cancer: Outside of Uranium Mines is it Relevant???
• Random finding does justify change in Byetta prescribing
• Ranking Hospitals Based on Their Demonstrable Value
• Reduction of systolic pressure decreases cognitive decline in susceptible individuals.
• Relationship between Angiotensin receptor blocker and Alzheime's disease
• Review of Statistical Conclusions of National Trends in Psychotherapy by Office-Based Psychiatrists
• Right Idea, Not Enough Incentive
• Risky of Safe: can be both depending on patient selection (just like all other drugs).
• Rite-Aid: From Worse to Awful
• Rules in Research are in place for a reason.
• Safety first?
• Safety Focus Slows New Drug Pipeline: Ba Humbug
• Salmonella; Cancer cells?? Let's not get carried away
• Saying "I'm Sorry" Will Decrease Medical Malpractice Premiums and Increase the Quality of Care
• Sepsis biomarker
• Signs That the Is Party Over?
• Skin Quality is an important consideration in Aging
• So Much for GVAX.... for now?
• So Much for Health "Insurance"
• So What?
• Sorafenib (Bayer) in hepatocellular carcinoma (HCC): already factored in!
• SRIMEERA ASSOCIATES-ANL MADHAVANN
• SRIMEERA ASSOCIATES-ANL MADHAVANN
• SRIMEERA ASSOCIATES-ANL MADHAVANN
• SRIMEERA ASSOCIATES-ANL MADHAVANN
• SRIMEERA ASSOCIATES-ANL MADHAVANN
• Starting Younger Every Day
• Statin therapy for children
• Statins for Kids! It's gone too far !!!
• Statistics can prove anything
• Stents vs Coronary Surgery
• Stents vs. Drugs: Same for Patients, Very Different for Providers
• Study Matches Cure Rates and Tumor Control of US Treatment Methods
• Sunitinib vs Interferon: No contest at the onset
• Superinfection
• Symbicort will give a lift to the little ones
• Systemic Inflammation as a Sign of Cardiovascular Health and Link to Alzheimers
• Taking money for doing research is not unethical.
• Talecris IVIg Product Gets FDA Approval for Serious Neurological Disorder
• TANSTAAFL
• Targeted therapy for myeloproliferative disorders (MPD) from Cephalon
• Temozolomide and Thalidomide combination therapy for Malignant Melanoma
• The Dark Side of Fosamax
• The Devil Is in the Details
• The effect of a slowing economy on dental practices
• The Extent is More Troubling that the Fact
• The FInal Cervical cancer Vaccine is media hype
• The folly of biofuels
• The Healthcare Industry Is Not Immune
• The heck with the impact on Roche. How about the patients??
• The New PhRMA “Code on Interactions with Health Care Professionals”: What will it mean?
• The other shoe falls II: Amgen and J & J will not be happy.
• The Pleitropic Effects of Volatile Anesthetics: Pain and Inhaled Agents?
• The Reality of Orthopaedics
• The Technology Needs Impact of Consumer Directed Healthcare on Providers
• The trial that is all about hype
• there are some, but basics in dermatology are why we are good at the cosmetics
• There is a hope for NHL ( Non-Hodgkin's Lymphoma).
• There is a need for a total joint registry in the United States
• They'll fix this before the end of the month
• Think about the future and what this will lead to....
• This is bad news for Cell Genesys but may use for other treatment
• This is going to be a huge fiasco
• This is not new news about Avastin
• This makes a lot of cents...
• This may have a market after all
• Tomotherapy, Protons, Short Course Breast RT - ASTRO 2008
• Too much of a good thing
• Transgene's vaccine for SCLC: Promising, BUT need to await survival and Phase III data
• Transparency in Healthcare: How to Assess?
• Transparency Without IT Solutions Lacks Substance
• Treatment of Male Lower Urinary Tract Symptoms secondary to BPH with Phosphodiesterase Type 5 Inhibitors
• Trends for Chronic Kidney Disease (CKD)
• Trust and "intelligence"
• UK the model for US healthcare?
• Ultimately, the Patient, Not the Payor, is the Customer
• Underutilization of EMR is no surprise
• UNITED THERAPEUTICS (UTHR) SET TO ACCELERATE REVENUE GROWTH WITH FILING OF INHALED TREPROSTINIL NDA
• Updating Pricing on Brand to Generic Drugs are Timing and Inventory Issues for Payers and Providers
• Velcade 1st line? No surprise.....
• Velcade as up front therapy for myeloma
• Velcade has multiple efficcay
• Velcade in myeloma 1st line. Am I s?urprised
• Veterans Admininstration Sets The Standard for Electronic Medical Records: Why Re-invent The Wheel?
• Visian ICL: Premium Channel for the Extremely Nearsighted
• Walgreens’ $4.33 Surrender to Wal-Mart
• Wal-Mart + Caterpillar: The Future of PBM & Pharmacy?
• We can't afford to practice the "best" medicine
• What can we all do to assure progress in the battle against the disease and its complications? Surrogate Endpoints, or do we wait for burials?
• What do you expect in hard economic times?
• What ever happens I can assure you the Doctors will be f........
• What is the likelihood of real Healthcare Reform?
• What Today's Health Care Provider Billing System's Need Under Consumer Directed Health Plans
• Who cares?
• Who Will Benefit Most?
• Wholesaler Impact of a Longs Drug Deal
• who's to blame?
• why are we going backwards
• why I am not ready to use electronic records
• why not do cosmetic surgery/procedures? why not get paid?
• Why Not?
• Will access to dermatology care suffer with increased cosmetic procedures ?
• Will Fewer "Never Events" Translate to Lower Medical Liability Costs?
• Will prescription drug spending decreases affect dermatology?
• Will Xolair Become Obsolete in the Treatment of Allergies?
• Witty approach by Mr. Witty to improve Glaxo's drug pipeline
• Working with Silcione Hydrogels is not easy!
• Yes - please stop the cycle of 70 deaths then pull the drug!
• Yes to finding new clincal uses for old drugs
• yes!